This stock will need some sort of catalyst for a re-rate.
Increased divs, progress on the pharma, pricing for the big harvests or even a substantial holder notice (that isn't UBS).
Failing that I think it will trade strongly leading up to the yearly results but until then who knows.
Interestingly there is big volumes on the buy side, and like yesterday I think this will close strongly.
An Updated Analysis, page-9
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)